GSK vs. RHHBY
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Roche Holding AG (RHHBY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or RHHBY.
Correlation
The correlation between GSK and RHHBY is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GSK vs. RHHBY - Performance Comparison
Key characteristics
GSK:
-0.15
RHHBY:
1.37
GSK:
-0.02
RHHBY:
1.88
GSK:
1.00
RHHBY:
1.26
GSK:
-0.14
RHHBY:
0.81
GSK:
-0.24
RHHBY:
3.95
GSK:
16.08%
RHHBY:
8.33%
GSK:
26.52%
RHHBY:
24.10%
GSK:
-55.21%
RHHBY:
-50.12%
GSK:
-15.45%
RHHBY:
-16.91%
Fundamentals
GSK:
$75.01B
RHHBY:
$252.62B
GSK:
$1.66
RHHBY:
$1.59
GSK:
22.31
RHHBY:
24.62
GSK:
0.35
RHHBY:
0.62
GSK:
2.39
RHHBY:
4.05
GSK:
4.10
RHHBY:
6.34
Returns By Period
In the year-to-date period, GSK achieves a 12.10% return, which is significantly lower than RHHBY's 17.75% return. Over the past 10 years, GSK has underperformed RHHBY with an annualized return of 2.59%, while RHHBY has yielded a comparatively higher 4.37% annualized return.
GSK
12.10%
-2.80%
1.60%
-4.49%
1.61%
2.59%
RHHBY
17.75%
-5.32%
1.44%
34.49%
0.86%
4.37%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK vs. RHHBY — Risk-Adjusted Performance Rank
GSK
RHHBY
GSK vs. RHHBY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Roche Holding AG (RHHBY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GSK vs. RHHBY - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 4.14%, more than RHHBY's 3.43% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.14% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
RHHBY Roche Holding AG | 3.43% | 3.99% | 3.55% | 3.23% | 2.47% | 2.63% | 2.69% | 3.58% | 3.22% | 3.62% | 3.14% | 3.23% |
Drawdowns
GSK vs. RHHBY - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.21%, which is greater than RHHBY's maximum drawdown of -50.12%. Use the drawdown chart below to compare losses from any high point for GSK and RHHBY. For additional features, visit the drawdowns tool.
Volatility
GSK vs. RHHBY - Volatility Comparison
GlaxoSmithKline plc (GSK) and Roche Holding AG (RHHBY) have volatilities of 11.17% and 10.99%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GSK vs. RHHBY - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Roche Holding AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities